|
|||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||
![]() |
|||||||||||||||||||||||||||||||
|
Marinus has many distinguished advisors and collaborators who have partnered in developing ganaxolone for the treatment of epilepsy, posttraumatic stress disorder and fragile-X syndrome. ClinicalJacqueline A. French, M.D. – Epilepsy Center, New York University John Pellock, M.D. – Medical College of Virginia, Virginia Commonwealth University Regulatory Cynthia McCormick, M.D. – McCormick Consulting Toxicology Raymond Stoll, Ph.D. Pharmacokinetics Henry J. Pieniaszek, Jr., Ph.D. – HPP Consulting & Services, Inc. |
||||||||||||||||||||||||||||||
| © Marinus Pharmaceuticals | |||||||||||||||||||||||||||||||